57734-44-8

Usage

Uses

Used in Pharmaceutical Industry:
(1-benzylpyrrolidin-2-yl)methanamine is used as a psychoactive substance for its potential therapeutic effects. It is being studied for its possible role in the treatment of psychiatric disorders or addiction due to its action as a selective dopamine reuptake inhibitor.
Used in Research and Development:
(1-benzylpyrrolidin-2-yl)methanamine is used as a subject of research for understanding its pharmacological properties and potential risks. Ongoing research aims to explore its efficacy and safety in various applications, particularly in the context of psychiatric treatments.

Upstream product

• 60169-70-2 1-benzylpyrrolidine-2-carboxamide 
• 60169-72-4 1-benzyl-pyrrolidine-2-carboxylic acid 
• 201406-78-2 1-benzylpyrrolidine-2-carboxylic acid methyl ester 
• 2812-47-7 pyrrolidine-2-carboxylic acid amide 
• 93188-01-3 2-(aminocarbonyl)-1-pyrrolidinecarboxylic acid, phenylmethyl ester 
• 1148-11-4 N-carbobenzyloxyproline 
• 100-52-7 benzaldehyde 
• 6859-99-0 3-hydroxypiperazine 
• 14813-01-5 1-benzyl-3-hydroxypiperidine 
• 1227866-76-3 methanesulfonic acid (1-benzyl-piperidin-3-yl)methyl ester 
• 60169-68-8 2-azidomethyl-1-benzylpyrrolidine 

Downstream Products

• 96695-98-6 N-(1-benzyl-2-pyrrolidinylmethyl)-2-methyl-5-sulfamoyl-2,3-dihydrobenzofuran-7-carboxamide 
• 132020-42-9 N-(1-Benzyl-pyrrolidin-2-ylmethyl)-3-bromo-2-hydroxy-6-methoxy-benzamide 
• 82689-90-5 N-(1-Benzyl-pyrrolidin-2-ylmethyl)-5-chloro-2-methoxy-4-methylamino-benzamide 
• 72412-48-7 2-Amino-4-methoxy-pyrimidine-5-carboxylic acid (1-benzyl-pyrrolidin-2-ylmethyl)-amide 
• 84332-26-3 2-Dimethylamino-4-methoxy-pyrimidine-5-carboxylic acid (1-benzyl-pyrrolidin-2-ylmethyl)-amide; hydrochloride 
• 121998-21-8 1-benzyl-2-<(trifluoroacetylamino)methyl>pyrrolidine 
• 84332-25-2 4-Methoxy-2-methylamino-pyrimidine-5-carboxylic acid (1-benzyl-pyrrolidin-2-ylmethyl)-amide; hydrochloride 
• 149649-57-0 (N-tert-butoxycarbonylaminomethyl)-N-benzylpyrrolidine 
• 60737-17-9 N-(1-benzyl-pyrrolidin-2-ylmethyl)-formamide 

Relevant academic research and scientific papers

PYRIDINE-3-CARBOXYAMIDE DERIVATIVE

To provide a novel JAK3 inhibitor that is useful as a preventive and/or therapeutic agent for rejection and graft versus host disease (GvHD) in organ transplantation, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, Sj?gren syndrome, Behcet's disease, type I diabetes mellitus, autoimmune thyroiditis, idiopathic thrombocytopenic purpura, ulcerative colitis, Crohn's disease, asthma, allergic rhinitis, atopic dermatitis, contact dermatitis, urticaria, eczema, psoriasis, allergic conjunctivitis, uveitis, cancer, leukemia and the like. The pyridine-3-carboxyamide derivative represented by the general formula (1): or its salt or a solvate thereof.

Catalytic epoxidation of unfunctionalized alkenes by dinuclear nickel(II) complexes

The synthesis, crystal and molecular structure and catalytic activity in epoxidation reactions of new dinuclear nickel(II)-complexes, octahedral μ-diacetato-μ-[2,6-bis[N-2-2'-pyridylethyl)formimidoyl]phenolato]bis nickel(II)·perchlorate·methanol (6) and square planar (μ-hydroxo-μ-[2,6-bis[N-((S)-1-benzyl-2-yl-pyrrolidine)formimidoyl]p henolato]bisnickel(II)·bisperchlorate (7), are described. For the preparation of 7 a new 5-step route for homochiral bisamine (S)-benzyl-2-aminomethyl-pyrrolidine (19) was developed starting from (S)-proline. Epoxidation of unfunctionalized alkenes with sodium hypochlorite and tert-butyl hydroperoxide as terminal oxidants was effectively catalyzed with bisnickel(II)-complexes 6 and 7, and a turnover of 165 was reached using trans-β-methylstyrene (34). The epoxidations probably proceed via a radical intermediate (such as OCl·) and no enantioselectivity is obtained under phase transfer conditions. In epoxidation reactions employing tert-butyl hydroperoxide as terminal oxidant a turnover of 43 was obtained with trans-stilbene (30) as substrate. Unexpectedly in the case of styrene (29) 1,2-bis-(tert-butylperoxy)ethylbenzene (59) was isolated as the major product.

N-(1-benzyl pyrrolidinyl 2-alkyl) substituted benzamides and derivatives thereof

The benzamides of this invention and their pharmaceutically acceptable salts are particularly effective in the treatment of emesis and ulcers in mammals. Their low level of toxicity is compatible with use in human therapy, without undesirable side effects.